Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer

Recruiting now · Phase 3

Conditions studied: Breast Cancer Metastatic

In brief

DOTABREAST: Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer This is a prospective, monocentric, non-controlled, non-randomized, open-label, interventional study.

Key facts

Study ID: NCT06611891
Run by: University Hospital, Grenoble
People needed: 25
Starts: 2025-01-06
Expected to finish: 2026-10-01
Last updated by the study team: 2025-03-04

Who can join

Age: 18 and older, up to 99. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Age over 18
Patients with metastatic breast cancer who have completed at least one first line of systemic therapy for metastatic breast cancer
Patient labeled on the primary lesion ER+HER2- (20)
Presence of metastatic liver and bone lesions identifiable with 18F-FDG PET-Scan
Presence of at least 10 identifiable secondary lesions in 18F-FDG PET-Scan
No therapeutic change between 18F-FDG PET-Scan and 68Ga-DOTATOC PET-Scan.
Performing the PET scan with 68Ga-DOTATOC within a maximum of 21 days after the 18F-FDG PET-Scan
Person affiliated to or benefiting from social security
Person who has given written informed consent

You may not qualify if…

Patients followed or with history of other active neoplastic pathology (including neuroendocrine tumor)
Known allergy to 68Ga-DOTATOC or its excipients
Subject refusing to sign the consent to participate
Minor subject
Subject excluded from another study
Persons referred to Articles L1121-5 to L1121-8 of the Public Health Code (CSP)
Subject cannot be contacted in case of emergency

Where it is running

CHU Grenoble Alpes — Grenoble, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.